Literature DB >> 19165579

The science of USP 1 and 2 dissolution: present challenges and future relevance.

Vivian Gray1, Gregg Kelly, Min Xia, Chris Butler, Saji Thomas, Stephen Mayock.   

Abstract

Since its inception, the dissolution test has come under increasing levels of scrutiny regarding its relevance, especially to the correlation of results to levels of drug in blood. The technique is discussed, limited to solid oral dosage forms, beginning with the scientific origins of the dissolution test, followed by a discussion of the roles of dissolution in product development, consistent batch manufacture (QC release), and stability testing. The ultimate role of dissolution testing, "to have the results correlated to in vivo results or in vivo in vitro correlation," is reviewed. The recent debate on mechanical calibration versus performance testing using USP calibrator tablets is presented, followed by a discussion of variability and hydrodynamics of USP Apparatus 1 and Apparatus 2. Finally, the future of dissolution testing is discussed in terms of new initiatives in the industry such as quality by design (QbD), process analytical technology (PAT), and design of experiments (DOE).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165579     DOI: 10.1007/s11095-008-9822-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  68 in total

1.  Effect of aging on the dissolution stability of glibenclamide/beta-cyclodextrin complex.

Authors:  R J Babu; J K Pandit
Journal:  Drug Dev Ind Pharm       Date:  1999-11       Impact factor: 3.225

2.  Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system.

Authors:  Jennifer L Baxter; Joseph Kukura; Fernando J Muzzio
Journal:  AAPS J       Date:  2006-01-03       Impact factor: 4.009

3.  A process analytical technology approach based on near infrared spectroscopy: tablet hardness, content uniformity, and dissolution test measurements of intact tablets.

Authors:  Marcelo Blanco; Manel Alcalá; Josep M González; Ester Torras
Journal:  J Pharm Sci       Date:  2006-10       Impact factor: 3.534

4.  Report of the workshop on in vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms.

Authors:  J P Skelley; G L Amidon; W H Barr; L Z Benet; J E Carter; J R Robinson; V P Shah; A Yacobi
Journal:  J Pharm Sci       Date:  1990-09       Impact factor: 3.534

5.  In-vitro dissolution profile comparison: statistics and analysis, model dependent approach.

Authors:  P M Sathe; Y Tsong; V P Shah
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

6.  Factors influencing comparative bioavailability of spironolactone tablets.

Authors:  J M Clarke; L E Ramsay; J R Shelton; M J Tidd; S Murray; R F Palmer
Journal:  J Pharm Sci       Date:  1977-10       Impact factor: 3.534

7.  A novel in vitro release method for submicron sized dispersed systems.

Authors:  N Chidambaram; D J Burgess
Journal:  AAPS PharmSci       Date:  1999

8.  Systematic error associated with apparatus 2 of the USP dissolution test II: Effects of deviations in vessel curvature from that of a sphere.

Authors:  D C Cox; C E Wells; W B Furman; T S Savage; A C King
Journal:  J Pharm Sci       Date:  1982-04       Impact factor: 3.534

9.  Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).

Authors:  Sandeep Dutta; Yihong Qiu; Emil Samara; Guoliang Cao; G Richard Granneman
Journal:  J Pharm Sci       Date:  2005-09       Impact factor: 3.534

10.  Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.

Authors:  Ekarat Jantratid; Sompol Prakongpan; Gordon L Amidon; Jennifer B Dressman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

View more
  14 in total

1.  Advancing Product Quality: a Summary of the Second FDA/PQRI Conference.

Authors:  Lawrence X Yu; Ilgaz Akseli; Barbara Allen; Gregory Amidon; Tara Gooen Bizjak; Ashley Boam; Margaret Caulk; David Doleski; Joseph Famulare; Adam C Fisher; Scott Furness; Brian Hasselbalch; Henry Havel; Stephen W Hoag; Robert Iser; Bruce D Johnson; Robert Ju; Paula Katz; Emanuela Lacana; Sau L Lee; Richard Lostritto; Grace McNally; Mehul Mehta; Ganapathy Mohan; Moheb Nasr; Roger Nosal; Mary Oates; Thomas O'Connor; Jim Polli; G K Raju; Mahesh Ramanadham; Giuseppe Randazzo; Susan Rosencrance; Anna Schwendeman; Arzu Selen; Paul Seo; Vinod Shah; Ramesh Sood; Michael P Thien; Tony Tong; Bernhardt L Trout; Katherine Tyner; Siva Vaithiyalingam; Martin VanTrieste; Fionnuala Walsh; Russell Wesdyk; Janet Woodcock; Geoffrey Wu; Larisa Wu; Louis Yu; Diane Zezza
Journal:  AAPS J       Date:  2016-02-09       Impact factor: 4.009

2.  Development and Validation of a Discriminatory Dissolution Model for an Immediately Release Dosage Form by DOE and Statistical Approaches.

Authors:  Mingkun Fu; Ellen Conroy; Michael Byers; Lakshminarasimhan Pranatharthiharan; Thierry Bilbault
Journal:  AAPS PharmSciTech       Date:  2021-04-21       Impact factor: 3.246

Review 3.  Application of UV Imaging in Formulation Development.

Authors:  Yu Sun; Jesper Østergaard
Journal:  Pharm Res       Date:  2016-10-20       Impact factor: 4.200

4.  A new approach to dissolution testing by UV imaging and finite element simulations.

Authors:  Johan P Boetker; Jukka Rantanen; Thomas Rades; Anette Müllertz; Jesper Ostergaard; Henrik Jensen
Journal:  Pharm Res       Date:  2013-01-11       Impact factor: 4.200

Review 5.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

6.  Simulation of in vitro dissolution behavior using DDDPlus™.

Authors:  May Almukainzi; Arthur Okumu; Hai Wei; Raimar Löbenberg
Journal:  AAPS PharmSciTech       Date:  2014-11-20       Impact factor: 3.246

Review 7.  Benefits of Fractal Approaches in Solid Dosage Form Development.

Authors:  Renata Abreu-Villela; Martin Kuentz; Isidoro Caraballo
Journal:  Pharm Res       Date:  2019-09-06       Impact factor: 4.200

8.  Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations.

Authors:  Nicole Seeger; Sigrid Lange; Sandra Klein
Journal:  AAPS PharmSciTech       Date:  2015-06-24       Impact factor: 3.246

9.  Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methods.

Authors:  J C Machado; A D Lange; V Todeschini; N M Volpato
Journal:  AAPS PharmSciTech       Date:  2013-11-22       Impact factor: 3.246

10.  Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1).

Authors:  Chris Brough; Dave A Miller; Justin M Keen; Shawn A Kucera; Dieter Lubda; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-12-04       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.